Publication | Open Access

507O EXCLAIM-2: Phase III trial of first-line (1L) mobocertinib versus platinum-based chemotherapy in patients (pts) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)+ locally advanced/metastatic NSCLC

OncologyMedicineMetronomic TherapyPhase Iii TrialClinical TrialsPharmacotherapyAdvanced/metastatic NsclcCancer TreatmentPharmacologyRadiation OncologyMolecular OncologyPlatinum-based ChemotherapyHealth Sciences